|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0205197,
umls-concept:C0205263,
umls-concept:C0282460,
umls-concept:C0684249,
umls-concept:C1513884,
umls-concept:C1516213,
umls-concept:C1521726,
umls-concept:C1521808,
umls-concept:C1522449,
umls-concept:C1628324,
umls-concept:C1696465,
umls-concept:C1704648,
umls-concept:C2603343
|
|
pubmed:issue |
27
|
|
pubmed:dateCreated |
2007-9-19
|
|
pubmed:abstractText |
This double-blind randomized phase II trial examined whether vandetanib, an inhibitor of vascular endothelial and epidermal growth factor receptors, could prolong progression-free survival in responding patients with small-cell lung cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AlamYasminY,
pubmed-author:ArnoldAndrew MAM,
pubmed-author:ButtsCharlesC,
pubmed-author:ChanAdrienA,
pubmed-author:DingKeyueK,
pubmed-author:DjurfeldtMarinaM,
pubmed-author:EllisPeterP,
pubmed-author:FindlayBrianB,
pubmed-author:GossGlenwoodG,
pubmed-author:GreggRichardR,
pubmed-author:LangmuirPeterP,
pubmed-author:LeeChristopher WCW,
pubmed-author:MeharchandJacintaJ,
pubmed-author:MeiS SSS,
pubmed-author:National Cancer Institute of Canada Clinical Trials Group Study BR.21,
pubmed-author:SeymourLesleyL,
pubmed-author:ShepherdFrancesF,
pubmed-author:SmylieMichaelM,
pubmed-author:WhiteheadMarloM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4278-84
|
|
pubmed:dateRevised |
2007-12-31
|
|
pubmed:meshHeading |
pubmed-meshheading:17878480-Adult,
pubmed-meshheading:17878480-Aged,
pubmed-meshheading:17878480-Carcinoma, Small Cell,
pubmed-meshheading:17878480-Combined Modality Therapy,
pubmed-meshheading:17878480-Disease-Free Survival,
pubmed-meshheading:17878480-Double-Blind Method,
pubmed-meshheading:17878480-Female,
pubmed-meshheading:17878480-Humans,
pubmed-meshheading:17878480-Lung Neoplasms,
pubmed-meshheading:17878480-Male,
pubmed-meshheading:17878480-Middle Aged,
pubmed-meshheading:17878480-Piperidines,
pubmed-meshheading:17878480-Placebos,
pubmed-meshheading:17878480-Quality of Life,
pubmed-meshheading:17878480-Quinazolines,
pubmed-meshheading:17878480-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
|
|
pubmed:affiliation |
National Cancer Institute of Canada-Clinical Trials Group, Kingston, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
